Results 1-4 of 4 (Search time: 0.002 seconds).
Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link | |
---|---|---|---|---|---|---|---|
1 | 2019 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | Han, Y; Chen, MK; Wang, HL; Hsu, JL; Li, CW ; Chu, YY; Liu, CX; Nie, L; Chan, LC; Yam, C; Wang, SC; He, GJ; Hortobagyi, GN; Tan, XD; Hung, MC | American journal of cancer research 9(3), 608-618 | |||
2 | 2016 | Deubiquitination and Stabilization of PD-L1 by CSN5. | Lim, SO; Li, CW ; Xia, W; Cha, JH; Chan, LC; Wu, Y; Chang, SS; Lin, WC; Hsu, JM; Hsu, YH; Kim, T; Chang, WC; Hsu, JL; Yamaguchi, H; Ding, Q; Wang, Y; Yang, Y; Chen, CH; Sahin, AA; Yu, D; Hortobagyi, GN; Hung, MC | Cancer cell 30(6), 925-939 | |||
3 | 2016 | Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. | Li, CW ; Lim, SO; Xia, W; Lee, HH; Chan, LC; Kuo, CW; Khoo, KH ; Chang, SS; Cha, JH; Kim, T; Hsu, JL; Wu, Y; Hsu, JM; Yamaguchi, H; Ding, Q; Wang, Y; Yao, J; Lee, CC; Wu, HJ; Sahin, AA; Allison, JP; Yu, D; Hortobagyi, GN; Hung, MC | Nature communications 7, 12632 | |||
4 | 2014 | Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. | Hsu, YH; Yao, J; Chan, LC; Wu, TJ; Hsu, JL; Fang, YF; Wei, Y; Wu, Y; Huang, WC; Liu, CL; Chang, YC; Wang, MY; Li, CW ; Shen, J; Chen, MK; Sahin, AA; Sood, A; Mills, GB; Yu, D; Hortobagyi, GN; Hung, MC | Cancer research 74(17), 4822-4835 |